Exicure is a startup based in the United States, most recent round Series B, 3 tracked investors.
Based in the United States, Exicure is a startup founded in 2009. Its most recent tracked round is Series B. Brouky records 3 investors associated with the company.
Exicure is a clinical-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets, with a current emphasis on hematologic diseases through its lead program burixafor (GPC-100).
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.